// App-Quantinova.ai

2988 : Pioneer Part 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib in Indolent Systemic Mastocytosis

Researchers

Presenter

  • Cem Akin

Principal Investigators

  • Jason Gotlib

  • Vito Sabato

  • Karin Hartmann

  • Sigurd Broesby-Olsen

  • Mariana Castells

  • Tsewang Tashi

  • Mark L. Heaney

  • Tracy I. George

  • Frank Siebenhaar

  • Deepti H. Radia

  • Massimo Triggiani

  • Paul van Daele

  • Daniel J. DeAngelo

  • Ivn Alvarez-Twose

  • Andreas Reiter

  • Peter Vadas

  • Patrizia Bonadonna

  • Paggy Hew

  • Hui-Min Lin

  • Maria Roche

  • Marcus Maurer

Medical Centers

  • University of Michigan, Ann Arbor, MI

  • Department of Pathology, Stanford Cancer Institute/Stanford University School of Medicine, Stanford, CA

  • Department of Immunology, Allergology and Rheumatology, University of Antwerp and Antwerp University Hospital, Antwerp, Belgium

  • University Hospital Basel, Basel, Switzerland

  • Department of Rheumatology and DANBIO, Odense University Hospital, Odense, Denmark

  • Brigham and Women's Hospital, Brookline, MA

  • Hunstman Cancer Institute of Utah, Salt Lake City, UT

  • Columbia University Medical Center, New York, NY

  • ARUP Laboratories, University of Utah, Salt Lake City, UT

  • Corporate Member of Freie Universität Berlin, Humboldt - Universität zu Berlin, Dermatological Allergology, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany

  • Department of Medical Oncology, Guys and St Thomas NHS Foundation Trust, London, United Kingdom

  • Department of Medicine, Division of Allergy and Clinical Immunology,University of Salerno,Salerno,Italy

  • Internal Medicine, Erasmus Medical Center, Rotterdam,Netherlands

  • Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA

  • Instituto de Estudios de Mastocitosis de Castilla La Mancha, Hospital Virgen del Valle, Toledo, Spain

  • University Hospital Mannheim, Heidelberg University, Mannheim, Germany

  • Division of Allergy and Immunology, St. Michael's Hospital, Toronto, Canada

  • USD di Allergologia, Azienda Ospedaliera Universitaria Integrata di Verona, Centro Ricerche Cliniche di Verona, Verona, Italy

  • Blueprint Medicines Corporation, Cambridge, MA

  • Blueprint Medicines, Cambridge, MA

Locations

  • United States

  • Netherlands

  • Belgium

  • Switzerland

  • Denmark

  • Germany

  • United Kingdom

  • Italy

  • Spain

  • Canada

Companies

  • Blueprint Medicines

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Mastocytosis

Biomarkers

  • KIT Proto-Oncogene, Receptor Tyrosine Kinase

  • Solute Carrier Family 12 Member 2

Drug/Treatment

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Open Label

  • Superiority

  • Controlled

Phase

  • NA

Study Id's

  • NCT03731260

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved